Talking Oncology открытые
[search 0]
Больше

Download the App!

show episodes
 
A
All Talk Oncology Podcast

1
All Talk Oncology Podcast

Kenny Perkins - The Cancer Guy

Unsubscribe
Unsubscribe
Ежемесячно
 
All Talk Oncology is a Cancer Podcast that empowers cancer patients through insightful conversations that reinforces confidence and certainty about their cancer condition. Transforming a terrifying experience into a manageable one, by arming patients with the understanding they need, and the ability to take control of their treatments through knowledge, allowing effective interaction with their medical team.
 
Welcome to Integrative Oncology Talk, where we discuss the latest science and opinions from leading voices in integrative oncology. Integrative oncology utilizes complementary therapies and lifestyle strategies to help those affected by cancer, using personalized approaches and evidence-based recommendations. Dr. Santosh Rao, a medical oncologist and integrative oncologist, hosts this podcast, with support from the Society for Integrative Oncology, an international multidisciplinary organiza ...
 
Loading …
show series
 
Anti-HER2 agent classes Cleopatra Trial Later line options Leptomeningeal carcinomatosis Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, …
 
This episode is Research Review, a quarterly review of the research you may have missed. Today, we are covering the American Society of Hematology Annual Meeting highlights. First Up, results from the ECOG-ACRIN E1910 Randomized Phase III clinical trial showed that blinatumomab improved overall survival in newly diagnosed adult patients with b-line…
 
Listen in as we discuss cancer advocacy with some amazing cancer warriors at the Healthy eMatters Conference in Toronto, Canada. Learn how cancer advocacy is a rewards calling and how helping others can be such a honor. We also discuss the challenges and fears that come with being an advocate but through knowledge and understand you can master thos…
 
We speak with Drs. Ana Maria Lopez and Eleanor Walker on Health equity, how it can cause gaps in cancer care, and how we can address it with integrative oncology. Dr. Lopez and Dr. Walker both co-chair the Health Equity, Inclusion and Belonging Task Force of the Society for Integrative Oncology. Dr. Ana Maria Lopez is Professor and Vice Chair of Me…
 
HER-2 Low Breast Cancer and Sacutuzumab Govetecan HER-2 Testing Algorithm Trastuzumab Deruxtecan in HER-2 Low MBC 2:1 Randomization, Treatment of Provider Choice Sacutuzumab Govetacan for later line TNBC and HR positive MBC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and …
 
Sarcoma represents an incredibly rare group of cancers comprised of 50 histologic subtypes, with approximately 13,000 new diagnoses per year. Each histologic type exhibits a unique biologic behavior, and, as such, prognosis and optimal treatment strategies vary. Sarcoma can appear anywhere in the body, and local invasion of nearby organs may make s…
 
A study using chimeric antigen receptor (CAR)-T cells has proven to be safe for treating patients with relapsed or refractory acute myeloid leukemia (AML). The agent known as PRGN-3006 also brought remissions among patients who had chemotherapy for lymphodepletion prior to their CAR-T cell procedure (Abstract 4633). After the lead author of the new…
 
1. Endocrine Resistance: Definition and Mechanism 2. Role of AI with and without CDK4/6 inhibitors 3. Later line management of metastatic disease 4. Informative Censoring and the BOLERO-2 trial Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encour…
 
In this episode we turn our attention Anna Tower-Kovesdi. Listen in as she discusses her battle with Leukemia and how she learned to gather strength from her core values. Anna talks about courage, treatments, and how not to loose faith in the process. This is an episode you do not want to miss. You can visit our following platforms: Website: alltal…
 
Colorectal cancer is the third most diagnosed cancer and the second leading cause of cancer deaths worldwide. The current gold standard for screening, the colonoscopy, reduces cancer deaths by 67 percent, according to a 2018 study from Kaiser Permanente. So, we know screening is effective. However, obstacles remain. Colonoscopies are invasive and c…
 
1. Recurrence Risk Scores 2. TailorRx, RxPonder, MINDACT Trials Overview 3. Introduction to CDK 4/6 inhibitors 4. PALLAS and MONARCH-E Discussion Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO…
 
BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor—the investigational drug ipatasertib—in a Phase I study reported at the 2022 EORTC—NCI—AACR symposium on Molecular Targets and Cancer Therapeutics. Nearly a quarter of the patients treated with the AKT blocker had their tumors …
 
BARCELONA, Spain—Liquid biopsies are increasingly used to identify cancer progression and could also provide molecular evidence of higher risk for hematologic malignancies and solid tumors, according to findings from a study of circulating tumor DNA reported at the European Organization for Research and Treatment of Cancer—National Cancer Institute…
 
1. Tamoxifen, its development, mechanism and benefits 2. Aromatase inhibitors and their benefit in post-menopausal state 3. Nuances on extended endocrine therapy beyond 5 years 4. SOFT/TEXT, a broad overview of a complex publication Citations As always, citations, and sources include education from our respective training programs, the Devita textb…
 
In oncology today, there is an urgent need to better understand the implications of racial bias and disparities on the health outcomes of patients. Although breast cancer mortality rates decreased by 43 percent from 1989 to 2020, Black women remain more likely to die from breast cancer compared with White women, according to the 2022 American Cance…
 
We talk to Naveen Pemmaraju, MD, about the results of the largest prospective BPDCN trial evaluating the CD123-targeted therapy tagraxofusp in adults with treatment-naive and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare and aggressive myeloid malignancy of the dendritic cell lineage which can affect othe…
 
1. First, second, and third generation chemotherapy regimens 2. Considerations for anthracyclines 3. Considerations for taxanes 4. Adjuvant bisphosphonates Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by …
 
In this episode we turn our attention to empowerment health coach and cancer warrior Anuschka Alborzian. Learn how her positive attitude and strong mindset gave her the strength to fight. She discusses how perspective plays a huge role in healing and the things we say to ourselves matter. This is an episode you do not want to miss. You can visit ou…
 
Today on OncTimes Talk, we are getting to know a clinical researcher in 5 questions. We sat down with Sandeep Mittan, PhD, FAHA, who is a Clinical Scientist in the Division of Women’s Health and Medical Oncology at the Montefiore Medical Center and The University Hospital for Albert Einstein College of Medicine in New York. His work investigates me…
 
1. History of surgery and radiation for breast cancer 2. Indication and goal of adjuvant systemic therapy (incl cell-kill hypothesis) 3. Overview of breast cancer subtypes 4. Strategies and guidelines for surveillance Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptoda…
 
PARIS, France—One of the most prominent late-breaking abstracts reported at ESMO 2022 in Paris was about a rare cancer, desmoid tumor, for which no standard therapy had yet been recommended and for which there had been a clear unmet need. A team from Germany presented new findings from a randomized study using nirogacestat, a “NOTCH inhibitor”—gamm…
 
The availability of a blood test for circulating DNA that can be used widely in healthy individuals to check for molecular signs of multiple cancers led Deb Schrag, MD, MPH, formerly of the Dana-Farber Cancer Center in Boston and currently Chair of the Department of Medicine at Memorial Sloan-Kettering Cancer Center, New York, to research it's use …
 
1. Overview of disease site 2. Management of localized disease 3. Surveillance 4. Metastatic Disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cance…
 
1. RAPIDO Trial 2. PRODIGE-23 Trial 3. OPRA Trial 4. Evidence for non-operative potential in MSI-H tumors with immune checkpoint inhibition Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg.…
 
When it comes to strength and battling a rare form of cancer, we turn our attention to Amanda Lyons. She is an Artist, Poet, and a best selling author of the book Mango Dew. Learn how she over came the battle of Ewing Sarcoma. Amanda has a warriors mentality that has allowed her to thrive in her day to day activities. This is an episode you do not …
 
Journalist Peter Goodwin gives OncTimes Talk a whirlwind review of the top 2022 breast cancer research as he reports live in person from the 2022 ESMO Berlin meeting. Featuring the following interviews with leading experts: 1. Patient-Reported Outcomes Support First-Line Pembrolizumab in TNBC: David Cescon, MD, PhD, Medical Oncologist and Clinician…
 
1. Anatomy, definitions, and unique considerations vs colon cancer 2. Surgical modalities and patterns of failure 3. Perioperative radiation and chemoradiation 4. Evidence to support adjuvant systemic therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com De…
 
In this edition of OncTimes Talk we’re taking a look at: extending life in patients with metastatic hormone-sensitive prostate cancer by adding a third drug to standard two-drug regimens. In the randomized Phase III ARASENS trial—just published in the New England Journal of Medicine—the androgen receptor inhibitor, darolutamide, was compared with p…
 
1. Overview of intrahepatic, perihilar, distal cholangiocarcinoma 2. Overview of gall bladder adenocarcinoma 3. Adjuvant chemoradiation and chemotherapy considerations 4. Per-protocol, intention to treat analysis, historical controls Citations As always, citations, and sources include education from our respective training programs, the Devita text…
 
CAMBRIDGE, UK—OncTimesTalk visits genetics pioneer Nitzan Rosenfeld PhD, group leader at the Cancer Research UK Cambridge Institute, University of Cambridge, to learn about giant steps forward for lung cancer management—reported in the Annals of Oncology—made with the sensitive assay for circulating tumor DNA (ctDNA) they developed (2022; https://d…
 
1. Overview of nomenclature, etiology and presentation 2. Management of symptoms and prognosis 3. Systemic therapy in the first line 4. Second line and biomarker driven management Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodo…
 
1. Differential for pancreatic lesion, staging of adenocarcinoma 2. Surgical considerations, post-surgical complications 3. Historical adjuvant evidence 4. An argument for neoadjuvant systemic therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vi…
 
At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin interviewed Marla Lipsyc-Sharf, MD, Medical Oncology Fellow at Dana-Farber Cancer Institute/Mass General Brigham, who reported what she believes is the first data on ctDNA detection in late adjuvant, hormone receptor-positive breast cancer. The research showed ctDNA testing was …
 
In this podcast, we discuss the microbiome, how the microbiome has an effect on health, and how changes to the microbiome can effect cancer and responses to therapy. This is a rapidly evolving area of study.Dr. Jennifer Mcqaude is a Physician Scientist and Assistant Professor in Melanoma Medical Oncology at the University of Texas MD Anderson Cance…
 
1. Natural history of disease, presentation, and diagnosis 2. Principles of management 3. Landmark clinical trials 4. Targeted therapy options as of 2022 Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven…
 
All Talk Oncology had the privilege of interviewing celebrity makeup artist RaeDawn. She is an expert and the epitome of making people look good and feel good. Listen in as she shares her experience with cancer and how this eventually lead her to develop Balaeyon a product that not only hydrates, soothes and moisturizes the skin, but that can also …
 
At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin caught up with Julia C. Tchou, MD, PhD, FACS, from the University of Pennsylvania Health System, during her poster session. Her research examined the feasibility and acceptability of a weight loss group program via telehealth for breast cancer survivors.…
 
At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin caught up with Alexander I. Spira, MD, PhD, FACP after his presentation on KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation (Abstract 9002).…
 
1. Principles of management 2. Key chemotherapy tegimens 3. Immunotherapy/HER-2 Directed Approach 4. Alpha spending, hierarchical statistical design 5. Later line approach and bottom lines to approach Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vi…
 
Colleague Conversations offers insights into hematology/oncology from two different perspectives: a seasoned hematologist/oncologist and a clinician earlier in their career. Oncology Times reporter Catlin Nalley sat down with Lucy A. Godley, MD, PhD, and Gina Keiffer, MD, to discuss germline predisposition to hematologic malignancies. They delve in…
 
In this episode we turn our attention to cancer warrior JJ Singleton. Learn how he has taken a bad prognosis and has turned it into motivation to #nevergiveup Clinical trials are saving his life. This is an episode you do not want to miss! You can visit our following platforms: Website: alltalkoncology.com, Facebook, Instagram, and YouTube…
 
1. Anatomy of the Upper GI Tract 2. Diagnosis, Staging Work-up 3. Neoadjuvant Chemoradiation for Esophageal/EGJ 4. Perioperative and Adjuvant Gastric/EGJ 5. Checkmate 577 discussion Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theo…
 
A conversation about the emerging field of Supportive Oncology with one of the pioneers: The focus of this podcast will be on the intersection integrative oncology and supportive care .The reality: many centres, ours included are seeing integrative oncology/integrative medicine as part of supportive care . As Dr Berman and colleagues lead the way i…
 
IDEA Trial Discussion 1. Background/Methods 2. Non-inferiority Trial Design Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice …
 
As Russian forces continue to bombard Ukraine, concerns are mounting about the most vulnerable citizens there, including the ill and those with cancer. Today on OncTimes Talk, we review the war in Ukraine and discuss how the war is impacting cancer patients and health systems in neighboring countries. Trying to process the refugee flow is very daun…
 
In this episode we turn our attention to cancer warrior Kimberly Coleman. Learn how she discovered purpose during her cancer journey. Through her battle with colorectal cancer she has found resilience and strength in vulnerability. Listen in as she discusses qualities and tools that allow her to have a positive outlook on life. This is an episode y…
 
A bilateral prophylactic mastectomy for women at high risk of developing breast cancer can reduce their risk of developing the disease by up to 90 percent, according to the National Cancer Institute. An increasing number of women, including young women, are taking up this option. And while the data shows mastectomy is an effective method of reducin…
 
1. Clinical Presentation, Pathology Evaluation 2. Chemotherapy Regimens in Adjuvant Setting 3. Approach to Stage 3 4. Approach to Stage 2 Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. D…
 
1. Background on molecular targeted agents 2. VEGF-inhibitors 3. EGFR inhibition 4. Left vs Right sided colon cancer 5. MSI-H/dMMR status Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. D…
 
Loading …

Краткое руководство